

1 Prediabetic risk and disease burden: A  
2 crosssectional survey of an Ayurveda hospital

3  
4  
5  
6  
7  
8

9 **ABSTRACT:**

**Aims:** To know the prevalence of prediabetes and diabetes among the health seekers visiting to an Ayurveda hospital, the survey study was conducted. Prediabetes is a serious health condition where blood sugar levels are higher than normal, but not high enough yet to be diagnosed as type 2 diabetes. Diabetes is one of the largest global health emergencies of this century, ranking among the 10 leading causes of mortality. Early screening is as essential as early diagnosis and treatment..

**Study design:** A cross-sectional survey study

**Place and duration of the study:** Department of Swasthavritta, Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Hassan, between January 2020 and December 2020.

**Methodology:** Laboratory registers accessed from Sri Dharmasthala Manjunatheshwara Ayurveda Medical College and Hospital, Hassan, Karnataka. Guidelines of Centers for Disease Control and Prevention was used to detect prediabetes and diabetes.

**Results:** The preliminary report on the survey study conducted for one year during 2020 showed among the subjects tested for blood and urine sugars, around 13% were prediabetics and 27% were diabetics.

**Conclusion:** Awareness among public and healthcare professionals regarding etiological factors, risk factors are crucial in finding out prediabetics. Public visiting the hospital for health promotion, to improve quality of life must be encouraged to prevent non communicable diseases such as Diabetes.

10 *Keywords: Prevalence, prediabetes, diabetes, risk factor, survey, Ayurveda hospital*

11  
12  
13 **1. INTRODUCTION**  
14

15 “The burden of diabetes is expected to raise from 415 million individuals in 2015 to 642 million individuals  
16 by 2040. Most individuals pass through a phase of prediabetes before developing full-blown  
17 diabetes. Individuals older than 40 years of age and other high-risk individuals should be screened for  
18 diabetes. Because nearly all patients with T2DM(Diabetes mellitus-Type 2) pass through an extensive  
19 phase of prediabetes, targeting prediabetes with effective interventions can significantly alter the natural  
20 history of T2DM”. [1] “Prediabetes (intermediate hyperglycaemia) is a high-risk state for diabetes that is  
21 defined by glycaemic variables that are higher than normal, but lower than diabetes thresholds.

22 Prevalence of prediabetes is increasing worldwide. Observational evidence shows associations between  
23 prediabetes and early forms of nephropathy, chronic kidney disease, small fiber neuropathy, diabetic  
24 retinopathy, and increased risk of macrovascular disease”. [2] “The estimates in 2019 showed that 77  
25 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045.

26 Approximately 57% of these individuals remain undiagnosed. The prevention and management of  
27 diabetes and associated complications is a huge challenge in India due to several issues and barriers,  
28 including lack of multisectoral approach, surveillance data, awareness regarding diabetes, its risk factors  
29 and complications, access to health care settings, access to affordable medicines, etc. Thus, effective  
30 health promotion and primary prevention, at both, individual and population levels are the need of the  
31 hour”. [3] “Diagnosis of prediabetes is based on the presence of impaired fasting glucose, impaired  
32 glucose tolerance, and/or elevated HbA1c levels between 5.7% and 6.4%. Impaired glucose tolerance is  
33 defined as blood glucose levels of 140 to 199 mg/dL during a 75-gram oral glucose tolerance test (normal

< 140 mg/dL), and impaired fasting glucose is defined as blood glucose levels of 100 to 125 mg/dL, although the World Health Organization has a narrower threshold of between 110 and 125 mg/dL”.[4] “Prediabetes consists of impaired fasting glucose and/or impaired glucose tolerance and is a significant risk factor for the development of type 2 diabetes, microvascular, and macrovascular disease. The values used to define prediabetes are arbitrary, because prediabetes represents an intermediary category along the continuum from normal glucose levels and tolerance to overt hyperglycemia. The progression from prediabetes to type 2 diabetes occurs over many years, strong evidence to support intervention to delay the progression from prediabetes to diabetes. Large, randomized prospective studies with lifestyle intervention and/or various modes of pharmacotherapy have demonstrated successful delay of diabetes”. [5] “The latest estimates of the global prevalence of diabetes mellitus are in the range of 9.3% , while 1 out of 3 adults may fulfill the diagnostic criteria for prediabetes, although the latter is highly dependent on the used definition. However, irrespective of definition, prediabetic states share a high probability of progression to T2DM. Typical diabetes complications associated with chronic hyperglycemia, such as neuropathy, retinopathy, nephropathy and coronary artery disease may already be evident among patients with prediabetes. Although there are ongoing randomized trials to address the issue of prevention of complications through antihyperglycemic therapy at this stage, the principal strategies in prediabetic populations aim towards the prevention of progression to T2DM through lifestyle modification and, to a lesser extent, drug therapy. A diagnosis of prediabetes most often emerges during screening for T2DM, which is recommended for individuals with high-risk features, namely overweight or obesity plus one or more defined risk factors for dysglycemia. Even though diabetes and prediabetes become more prevalent with older age and demographic aging is a prominent cause for the racing diabetes pandemic, current recommendations do not consider advanced age (or any particular adult age for that matter) as a compelling risk factor regarding DM screening. Furthermore, elderly individuals are often grossly underrepresented in clinical trials for diabetes therapy or prevention . As a result, many issues regarding prediabetes detection, management and prevention of DM are yet to be conclusively addressed”.[6]. “There are other parameters to detect prediabetic risk, blood glucose levels are considered in this study. Impaired glucose tolerance (IGT) (2-h glucose 7.8–11.0 mol/L [140–199 mg/dL]) and impaired fasting glucose (IFG) (fasting glucose 6.1–6.9 mmol/L [110–125 mg/dL]), based on the World Health Organization (WHO) criteria, are commonly used to define prediabetes. IGT tends to be characterized by insulin resistance in muscle and decreased glucose uptake, while IFG is generally driven by insulin resistance in the liver and excess hepatic glucose production. There is limited overlap between IGT and IFG; only 20–25% of people with IGT have IFG, and 30–45% of individuals with IFG have IGT”[7].

## 2. MATERIAL AND METHODS:

**2.1. SOURCE OF DATA:** Laboratory registers of Sri Dharmasthala Manjunatheshwara Ayurveda Medical College and Hospital, Hassan, Karnataka

**2.2. STUDY PERIOD:** Data accessed from January 2020 to December 2020

**2.3. DIAGNOSTIC CRITERIA:** Prediabetes and diabetes were defined as shown in the image 1. [8] The results were explained in simple proportions

Result*	A1C Test	Fasting Blood Sugar Test	Glucose Tolerance Test	Random Blood Sugar Test
Diabetes	6.5% or above	126 mg/dL or above	200 mg/dL or above	200 mg/dL or above
Prediabetes	5.7 - 6.4%	100 - 125 mg/dL	140 - 199 mg/dL	N/A
Normal	Below 5.7%	99 mg/dL or below	140 mg/dL or below	N/A

**Image 1:** Diagnosis criteria of Diabetes, Prediabetes, Normal.


82 **3. RESULTS:**

83  
84 The results of the preliminary report on the survey study to know the prevalence of Prediabetic risk and  
85 diabetics those approached the hospital is as follows:  
86


87 **Table 1.** Observations on Data, showing number of laboratory investigations done during the year 2020,  
88 number of subjects tested for blood/urine sugar, identified prediabetics, diabetics, non-diabetics.  
89

90

No. of subjects tested for any of the laboratory investigations	122426
No. of subjects tested for Blood or Urine sugar	3099
No. of Normoglycemic subjects	1831
No. of Prediabetic subjects	407
No. Diabetic subjects	861



92  
93  
94 **Figure 1:** Pie diagram shows the number of subjects tested for any of blood/urine sugar  
95 investigations among the total subjects underwent any laboratory investigations.  
96  
97



100 **Figure 2:** Pie diagram shows prevalence of diabetes, prediabetes, non diabetes.  
101  
102  
103

104 **4. DISCUSSION:**

105  
106 The preliminary survey data showed about 1,22,426 subjects underwent either of hematology,  
107 biochemistry, serology or microbiological laboratory investigations. Among these, 3,099 subjects tested for

108 one or the other blood and urine sugar such as fasting and postprandial blood sugar, fasting and  
109 postprandial urine sugar, HbA1C, Random blood sugar, GTT. Normoglycemia subjects were found to be  
110 59% (1831), 27.78% (861) subjects were Diabetics followed by 13.13% (401) subjects were Prediabetics.  
111 The interim analysis report was presented in this work, the data collection will be continued and analysed  
112 based on the type of sugar test done, age, gender, locality. And also the data will be statistically  
113 analyzed. The overall prevalence of prediabetes and diabetes in all 15 states of India was 10.3% and  
114 7.3% respectively. The prevalence varied from state to state and there are large differences between the  
115 states in India. "The study reports an evidence of an epidemiological transition, with a higher prevalence  
116 of diabetes in low socioeconomic groups in the urban areas of the more economically developed states.  
117 The spread of diabetes to economically disadvantaged sections of society is a matter of great concern,  
118 warranting urgent preventive measures". [9] "The prevalence of prediabetes is increasing worldwide and it  
119 is projected that >470 million people will have prediabetes in 2030. Prediabetes is associated with the  
120 simultaneous presence of insulin resistance and  $\beta$ -cell dysfunction, abnormalities that start before  
121 glucose changes are detectable. Observational evidence shows associations of prediabetes with early  
122 forms of nephropathy, chronic kidney disease, small fibre neuropathy, diabetic retinopathy, and increased  
123 risk of macrovascular disease. Multifactorial risk scores could optimize the estimation of diabetes risk  
124 using non-invasive parameters and blood-based metabolic traits in addition to glycaemic values. For  
125 prediabetic individuals, lifestyle modification is the cornerstone of diabetes prevention with evidence of a  
126 40%–70% relative risk reduction. Accumulating data also suggests potential benefits from  
127 pharmacotherapy". [10] "The prevention and management of diabetes and associated complications is a  
128 huge challenge in India due to several issues and barriers, including lack of multisectoral approach,  
129 surveillance data, awareness regarding diabetes, its risk factors and complications, access to health care  
130 settings, access to affordable medicines, etc. Thus, effective health promotion and primary prevention, at  
131 both, individual and population levels are the need of the hour. The risk for diabetes is largely influence by  
132 ethnicity, age, obesity and physical inactivity, unhealthy diet, and behavioral habits in addition to genetics  
133 and family history. Good control of blood sugar blood pressure and blood lipid levels can prevent and/or  
134 delay the onset of diabetes complications". [11] "The progression from prediabetes to type 2 diabetes  
135 occurs over many years before the development of overt hyperglycemia seen in diabetes. The risk of  
136 progressing to diabetes depends on the degree of insulin resistance and deficiency of insulin secretion as  
137 well as other diabetes risk factors". [12] "As with prediabetic status, diabetes risk models provide a method  
138 for identifying individuals at risk of developing diabetes based on parameters available to the general  
139 practitioner. There is no single universally accepted diabetes prediction model and given that ethnicity is  
140 strongly related to diabetes risk, recalibration of prediction algorithms may be necessary when they are  
141 applied to different populations. Irrespective of the definition and diagnostic criteria used, the term  
142 prediabetes denotes a state of dysmetabolism with a high risk of progression to diabetes mellitus.  
143 Although diabetes-related complications may already be evident among individuals with prediabetes,  
144 interventions at this stage primarily aim to hinder the development of overt hyperglycemia rather than to  
145 prevent complications". [13] "Prediabetes is a term used to describe a state of metabolic dysregulation,  
146 which is distinguished by glucose levels above normal but lower than those diagnostic for diabetes  
147 mellitus. The results of the study may present a series of important implications in clinical practice. The  
148 first consideration would focus on the prognosis and natural history of prediabetes. Most importantly,  
149 screening should occur strictly after the physician has weighted that any preventive or therapeutic  
150 interventions that may arise based on screening results are likely to decisively affect patient prognosis  
151 and quality of life. Finally, regarding identified cases of prediabetes in this age group, further preventive  
152 strategies should focus on improving the overall health status, prognosis and quality of life of patients  
153 rather than explicitly target prevention of progression to T2DM. The prevalence of diabetes and  
154 prediabetes are higher in both urban and rural areas of India compared with earlier studies. With greater  
155 urbanisation, growth of the middle class and ageing of the population, one can expect huge increases in  
156 the numbers of people with diabetes in India in the future". [14] "Diabetes is one of the largest global  
157 health emergencies of this century, ranking among the 10 leading causes of mortality together with  
158 cardiovascular disease (CVD), respiratory disease, and cancer. According to the World Health  
159 Organization (WHO), non-communicable diseases (NCDs) accounted for 74% of deaths globally in 2019,  
160 of which, diabetes resulted in 1.6 million deaths, thus becoming the ninth leading cause of death globally.  
161 According to these estimates, there is an urgent need for improved diabetes screening. They also  
162 highlight the importance of identifying undiagnosed diabetes and providing appropriate and timely care as  
163 undiagnosed diabetes can have negative consequences such as an increased risk of diabetes related  
164 complications, increased healthcare use, and associated costs". [15]. Diabetes has long been recognized  
165 as an inflammatory disease. The components of the immune system are altered in type two diabetes. IL-2  
166 produced by CD4+ T lymphocytes has been hypothesized to be linked to diabetes mellitus, but a  
167 verification of this claim is limited in literature. The previous study revealed that the expression of IL-2  
168 mRNA was significantly ( $p < 0.05$ ) upregulated in type 2 diabetes mellitus and pre-diabetes groups

169 compared to the normal group ( $p < 0.05$ ). This suggests that IL-2 gene expression plays a pivotal role in  
170 the molecular mechanism that leads to the etiology of diabetes mellitus type 2. In the quest for the cure  
171 for diabetes mellitus, research on relevant molecular biomarkers that could be the ideal candidate for  
172 drug target is actively ongoing [16]. "Prediabetes and diabetes populations had a high prevalence and  
173 higher odds of Non-alcoholic fatty liver disease (NAFLD) relative to the normoglycemic population and  
174 HbA1c is an independent predictor of NAFLD severity in prediabetes and diabetes populations.  
175 Healthcare providers should screen prediabetes and diabetes populations for early detection of NAFLD  
176 and initiate treatments including lifestyle modification to prevent the progression to non-alcoholic  
177 steatohepatitis or liver cancer"[17].

## 178 5. CONCLUSION:

181 Diabetes is more a lifestyle disorder and is preventable. A strict diet and lifestyle modification, stress free  
182 life, active and physical fitness, conscious living are the choices. It requires the awareness about the  
183 disease in the patient, responsibility from the healthcare professionals. The pathophysiology of the  
184 disease can be reversed and managed if diagnosed earlier. Many studies have proved the prediabetic  
185 stage can be converted back to normoglycemia. Prediabetes is a high risk state where the individual  
186 acquiring diabetes can be prevented. To delay the progression and development of diabetes, there is a  
187 need to check on risk factors that are non modifiable like family history, genetic and modifiable risk factors  
188 like diet, physical activity, obesity. There is a need to bring up the model in identifying the at risk  
189 individuals. Screening at the earliest using various methods will help in early diagnosis and intervention.  
190 This will aid in preventing disease progression and leading to diabetic complications. The sugar levels  
191 higher than normal but less than hyperglycemic value will be generally paid no attention by the health  
192 seekers and healthcare providers. The right intervention imposed when an individual at risk of getting  
193 diabetes or wide approach if given to a diabetic, the quality of life will be improved.

## 194 ETHICAL APPROVAL

196 All authors hereby declare that all experiments have been examined and approved by the appropriate  
197 ethics committee and have therefore been performed in accordance with the ethical standards laid down  
198 in the 1964 Declaration of Helsinki.

## 199 CONSENT

201 As per international standard or university standard, patient(s) written consent has been collected and  
202 preserved by the author(s).

## 203 REFERENCES

- 204 1.Khetan, A.K. and Rajagopalan, S. (2018) 'Prediabetes', *Canadian Journal of Cardiology*, 34(5), pp.  
205 615–623. doi:10.1016/j.cjca.2017.12.030.
- 206 2.Tabák, A.G. *et al.* (2012) 'Prediabetes: A high-risk state for diabetes development', *The Lancet*,  
207 379(9833), pp. 2279–2290. doi:10.1016/s0140-6736(12)60283-9.
- 208 3.Mohan, V. and Pradeepa, R. (2021) 'Epidemiology of type 2 diabetes in India', *Indian Journal of*  
209 *Ophthalmology*, 69(11), p. 2932. doi:10.4103/ijo.ijo\_1627\_21.
- 210 4. Zand, A., Ibrahim, K. and Patham, B. (2018) 'Prediabetes: Why should we care?', *Methodist DeBakey*  
211 *Cardiovascular Journal*, 14(4), p. 289. doi:10.14797/mdcj-14-4-289.
- 212 5. Aroda, V.R. and Ratner, R. (2008a) 'Approach to the patient with Prediabetes', *The Journal of Clinical*  
213 *Endocrinology & Metabolism*, 93(9), pp. 3259–3265. doi:10.1210/jc.2008-1091.
- 214 6. Tsilingiris, D., Vallianou, N.G. and Dalamaga, M. (2021b) 'Prediabetes screening: Questionable  
215 benefits in the Golden Years', *Metabolism Open*, 10, p. 100091. doi:10.1016/j.metop.2021.100091.

- 220 7. Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, Magliano DJ, Selvin E.  
221 Global prevalence of prediabetes. *Diabetes care*. 2023 May 17;dc222376.
- 222 8. *Diabetes tests* (2023) *Centers for Disease Control and Prevention*. Available at:  
223 <https://www.cdc.gov/diabetes/basics/getting-tested.html> (Accessed: 30 July 2023).
- 224 9. Anjana, R.M. *et al.* (2017) 'Prevalence of diabetes and Prediabetes in 15 states of India: Results from  
225 the ICMR–INDIAB population-based cross-sectional study', *The Lancet Diabetes & Endocrinology*,  
226 5(8), pp. 585–596. doi:10.1016/s2213-8587(17)30174-2.
- 227 10. Tabák, A.G. *et al.* (2012) 'Prediabetes: A high-risk state for diabetes development', *The Lancet*,  
228 379(9833), pp. 2279–2290. doi:10.1016/s0140-6736(12)60283-9.
- 229 11. Mohan, V. and Pradeepa, R. (2021) 'Epidemiology of type 2 diabetes in India', *Indian Journal of*  
230 *Ophthalmology*, 69(11), p. 2932. doi:10.4103/ijo.ijo\_1627\_21.
- 231 12. Aroda, V.R. and Ratner, R. (2008b) 'Approach to the patient with Prediabetes', *The Journal of Clinical*  
232 *Endocrinology & Metabolism*, 93(9), pp. 3259–3265. doi:10.1210/jc.2008-1091.
- 233 13. Tsilingiris, D., Vallianou, N.G. and Dalamaga, M. (2021a) 'Prediabetes screening: Questionable  
234 benefits in the Golden Years', *Metabolism Open*, 10, p. 100091. doi:10.1016/j.metop.2021.100091.
- 235 14. Dimitrios Tsilingiris, Natalia G. Vallianou, Maria Dalamaga, Prediabetes  
236 screening: Questionable benefits in the golden years, *Metabolism Open*, Volume 10, 2021, 100091, ISSN  
237 2589-9368, <https://doi.org/10.1016/j.metop.2021.100091>.
- 238  
239 15. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. *Indian J Ophthalmol*. 2021  
240 Nov;69(11):2932-2938. doi:10.4103/ijo.IJO\_1627\_21. PMID: 34708726; PMCID:  
241 PMC8725109.
- 242  
243 16. Ogbole FA, Harold BA. Association of undiagnosed pre-diabetes and type-2 diabetes mellitus with  
244 interleukin-2 mRNA expression among adults in Bayelsa State, Nigeria. *IJRR*. 2023;10(5):210-5.
- 245  
246 17. Shaheen M, Schrode KM, Tedlos M, Pan D, Najjar SM, Friedman TC. Racial/ethnic and gender  
247 disparity in the severity of NAFLD among people with diabetes or prediabetes. *Frontiers in Physiology*.  
248 2023 Feb 20;14:1076730.
- 249